Merck & Company, Inc. vs Sarepta Therapeutics, Inc. — Stock Comparison
Merck & Company, Inc. (MRK) and Sarepta Therapeutics, Inc. (SRPT) are both listed on US exchanges. This page compares their Q·Score ratings, key fundamentals (P/E, margins, growth), and Wall Street analyst consensus side by side. Data sourced from Yahoo Finance and updated on each page load.
Merck & Company, Inc. scores ahead of Sarepta Therapeutics, Inc. on Q·Score (7 vs 5.9 out of 10), led by Quality (7.7 vs 4.6) and Sentiment (7.1 vs 4.3). Sarepta Therapeutics, Inc. scores higher on Valuation, reflecting stronger P/E and price-target positioning. Analyst consensus targets imply greater upside for SRPT (+25.5%) than for MRK (+13.9%).
Price Performance
Normalised to 100 at period start — shows relative performance.
Q·Score Breakdown
High-quality business with 19% return on equity and 14% profit margins.
Healthy balance sheet and financial position.
⚠ 21% of analysts rate it Sell or Strong Sell.
Analyst Consensus
Fundamentals
Frequently Asked Questions
MRK vs SRPT: which stock scores better overall?
Based on Q·Score, Merck & Company, Inc. (MRK) scores 7/10 versus Sarepta Therapeutics, Inc. (SRPT) at 5.9/10. The Q·Score measures five dimensions: Quality, Health, Growth, Valuation, and Sentiment. For informational purposes only — not financial advice.
Which has better revenue growth: MRK or SRPT?
Merck & Company, Inc. (MRK) scores higher on Growth (6.2/10 vs 5.2/10). Merck & Company, Inc. reports revenue growth (4.9% YoY) while Sarepta Therapeutics, Inc. reports (-1.9% YoY). Growth scores reflect revenue and earnings momentum relative to sector peers.
Is MRK or SRPT more attractively valued?
Sarepta Therapeutics, Inc. (SRPT) scores higher on Valuation (7.5/10 vs 6.7/10). MRK trades at 11.9× P/E versus SRPT at 6.4×. Valuation is assessed using P/E ratio, analyst price targets, and 52-week range positioning relative to sector peers.
What do analysts say about MRK vs SRPT?
There are 27 analysts covering MRK with a consensus price target of $129.74, and 23 analysts covering SRPT with a consensus target of $22.00. Analyst consensus ratings are aggregated from Wall Street research and do not constitute investment advice.
Which is more profitable: MRK or SRPT?
Merck & Company, Inc. (MRK) scores higher on Quality (7.7/10 vs 4.6/10). Net profit margin: MRK at 13.6%, SRPT at 3.0%. Quality scores reflect profit margins, return on equity, and free cash flow generation.
Which has stronger financial health: MRK or SRPT?
Sarepta Therapeutics, Inc. (SRPT) scores higher on Financial Health (7.7/10 vs 7/10). Market beta: MRK at 0.22, SRPT at 0.20. Health scores consider beta, debt-to-equity, and current ratio. All investments carry risk — this is not investment advice.
What are the market caps of MRK and SRPT?
Merck & Company, Inc. (MRK) has a market capitalisation of $281.2B, while Sarepta Therapeutics, Inc. (SRPT) has a market cap of $1.9B. Market cap data is sourced from Yahoo Finance and reflects the most recent available figures.
Do MRK or SRPT pay dividends?
MRK pays a dividend yield of 2.99%, while SRPT does not currently pay a dividend. Dividend yields fluctuate with share price and company payout decisions.
Related Comparisons
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →